Suppr超能文献

肺移植后闭塞性细支气管炎综合征中的骨膜蛋白。

Periostin in Bronchiolitis Obliterans Syndrome after Lung Transplant.

机构信息

Division of Allergy, Pulmonary and Critical Care Medicine, Department of Internal Medicine, Transplant Research Center, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan 50612, Republic of Korea.

Department of Internal Medicine, School of Medicine, Pusan National University, Busan 43241, Republic of Korea.

出版信息

Int J Mol Sci. 2024 Sep 27;25(19):10423. doi: 10.3390/ijms251910423.

Abstract

The utility of measuring serum periostin levels for predicting the occurrence of bronchiolitis obliterans syndrome (BOS) after lung transplantation remains underexplored. We analyzed differentially expressed genes (DEGs) between initially transplanted lung tissue and lung tissue with BOS from four patients. Periostin levels were assessed in 97 patients who had undergone lung transplantation 1 year post-transplantation and at the onset of BOS. The association between periostin levels and BOS, as well as their correlation with the decline in forced expiratory volume in one second (FEV1), was evaluated. Periostin levels in the BOS group were significantly higher than those in the control group ( < 0.001) and the stable group ( < 0.001). Periostin levels at the onset of BOS were significantly higher than those 1 year post-transplantation in the BOS group ( < 0.001). The serum periostin levels at the time of BOS diagnosis showed a positive correlation with the reduction in FEV1 (%) (r = 0.745, < 0.001). The increase in the serum periostin levels at the time of BOS diagnosis compared with those 1 year post-transplantation was positively correlated with reduction in FEV1 (%) (r = 0.753, < 0.001). Thus, serum periostin levels may serve as biomarkers for predicting a decline in lung function in patients with BOS after lung transplantation.

摘要

测量血清骨膜蛋白水平对预测肺移植后闭塞性细支气管炎综合征(BOS)发生的作用仍未得到充分探索。我们分析了 4 名患者最初移植的肺组织和发生 BOS 的肺组织之间的差异表达基因(DEG)。在肺移植后 1 年和 BOS 发病时,评估了 97 例接受肺移植的患者的骨膜蛋白水平。评估了骨膜蛋白水平与 BOS 的关系,以及与用力呼气量(FEV1)下降的相关性。BOS 组的骨膜蛋白水平明显高于对照组(<0.001)和稳定组(<0.001)。BOS 组发病时的骨膜蛋白水平明显高于移植后 1 年(<0.001)。BOS 诊断时的血清骨膜蛋白水平与 FEV1(%)的下降呈正相关(r=0.745,<0.001)。BOS 诊断时血清骨膜蛋白水平较移植后 1 年的升高与 FEV1(%)的降低呈正相关(r=0.753,<0.001)。因此,血清骨膜蛋白水平可能作为预测肺移植后 BOS 患者肺功能下降的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0eef/11477235/c409d3cd1f7a/ijms-25-10423-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验